GPP
EPZM

Great Point Partners’s Epizyme, Inc EPZM Stock Holding History

Great Point Partners’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,173,913
Closed -$26.9M – 46
2019
Q1 		$26.9M Buy
+2,173,913
New +$24.3M 2.67% 17

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Great Point Partners's EPZM Position: Q2 2019 in Review

Great Point Partners sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 2,173,913 shares — an estimated $26.9M sold.

Great Point Partners first reported a position in EPZM in Q1 2019 and held it in 1 quarter. The position peaked at $26.9M in Q1 2019. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

  • Great Point Partners reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
  • Great Point Partners sold 2,173,913 Epizyme, Inc shares in Q2 2019, an estimated $26.9M.
  • Great Point Partners first reported a position in Epizyme, Inc in Q1 2019 and held it in 1 quarter.
  • Great Point Partners's Epizyme, Inc position peaked at $26.9M in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on Great Point Partners's 13F filing for Q2 2019, filed 14 Aug 2019.